Veerabadran Dheenadhayalan
Overview
Explore the profile of Veerabadran Dheenadhayalan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
563
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hoft D, Blazevic A, Selimovic A, Turan A, Tennant J, Abate G, et al.
EBioMedicine
. 2016 Jun;
7:278-86.
PMID: 27322481
Background: We report a first-in-human trial evaluating safety and immunogenicity of a recombinant BCG, AERAS-422, over-expressing TB antigens Ag85A, Ag85B, and Rv3407 and expressing mutant perfringolysin. Methods: This was a...
2.
Fletcher H, Snowden M, Landry B, Rida W, Satti I, Harris S, et al.
Nat Commun
. 2016 May;
7:11633.
PMID: 27151680
No abstract available.
3.
Fletcher H, Snowden M, Landry B, Rida W, Satti I, Harris S, et al.
Nat Commun
. 2016 Apr;
7:11290.
PMID: 27068708
Vaccines to protect against tuberculosis (TB) are urgently needed. We performed a case-control analysis to identify immune correlates of TB disease risk in Bacille Calmette-Guerin (BCG) immunized infants from the...
4.
Sheehan S, Harris S, Satti I, Hokey D, Dheenadhayalan V, Stockdale L, et al.
PLoS One
. 2015 Nov;
10(11):e0141687.
PMID: 26529238
Background: MVA85A and AERAS-402 are two clinically advanced viral vectored TB vaccine candidates expressing Mycobacterium tuberculosis antigens designed to boost BCG-induced immunity. Clinical trials with candidate malaria vaccines have demonstrated...
5.
Churchyard G, Snowden M, Hokey D, Dheenadhayalan V, McClain J, Douoguih M, et al.
Vaccine
. 2015 Feb;
33(15):1890-6.
PMID: 25698492
Background: The safety and immunogenicity of a replication deficient adenovirus serotype 35 tuberculosis (TB) vaccine containing gene inserts for Antigens (Ag) 85A, Ag85B and TB10.4 (AERAS-402/AD35.TB-S) was evaluated in previously...
6.
Hokey D, Wachholder R, Darrah P, Bolton D, Barouch D, Hill K, et al.
Hum Vaccin Immunother
. 2014 Nov;
10(8):2199-210.
PMID: 25424923
Bacille Calmette-Guérin (BCG), the only licensed vaccine for the prevention of tuberculosis (TB), provides only limited protection against certain forms of Mycobacterium tuberculosis (Mtb) infection. While infection with Mtb can...
7.
Jin T, Tsao E, Goudsmit J, Dheenadhayalan V, Sadoff J
Vaccine
. 2010 May;
28(27):4369-75.
PMID: 20444437
A powder vaccine intended for aerosol delivery was formulated by spray drying the Ad35-vectored tuberculosis (TB) AERAS-402 vaccine with mannitol-based stabilizers. Thermodynamic properties, water absorption, particle size distribution and morphology...
8.
Skeiky Y, Dietrich J, Lasco T, Stagliano K, Dheenadhayalan V, Goetz M, et al.
Vaccine
. 2009 Nov;
28(4):1084-93.
PMID: 19896449
Despite the extensive success with the introduction of M. bovis Bacille Calmette-Guérin (BCG), tuberculosis (TB) remains a major global epidemic infecting between 8 and 9 million people annually with an...
9.
Sun R, Skeiky Y, Izzo A, Dheenadhayalan V, Imam Z, Penn E, et al.
Vaccine
. 2009 Jun;
27(33):4412-23.
PMID: 19500523
Mycobacterium tuberculosis (Mtb), the causative agent of tuberculosis (TB), has infected approximately two billion individuals worldwide with approximately 9.2 million new cases and 1.6 million deaths annually. Current efforts are...
10.
Derrick S, Perera L, Dheenadhayalan V, Yang A, Kolibab K, Morris S
Vaccine
. 2008 Sep;
26(48):6092-8.
PMID: 18809446
New post-exposure tuberculosis vaccination strategies are being developed to prevent disease in individuals latently infected with Mycobacterium tuberculosis. However, concerns about the potential induction of deleterious Koch-like reactions after immunization...